Natalizumab (Tysabri)-Associated PML Survival Rates Exceed 80%
AMSTERDAM—Early diagnosis through enhanced clinical vigilance and optimal management of progressive multifocal leukoencephalopathy (PML) may improve outcomes, according to data…
Natalizumab (Tysabri) Effective for Relapsing-Remitting MS
Natalizumab is well tolerated and reduces relapses and disability at two years in patients with relapsing-remitting multiple sclerosis, according to…
Stuart Schlossman
Two out of Three Patients Report Discontinuing Tysabri Without Doctors’ Advice
PatientsLikeMe Releases First in Series of Reports on Real-World Patient Experiences With Top Multiple Sclerosis Drugs CAMBRIDGE, MA–(Marketwire – Sep…
Stuart Schlossman
Clinical Reviews of JCV and PML in Digital.pdf format
A Digital View. Information provided by: Cherie C. Binns RN BS MSCN Understanding the complexities Click here: http://viewer.zmags.com/publication/f84595ef#/f84595ef/2 to review this Biogen Digital…
Stuart Schlossman
Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
– Host-Targeted Antiviral Blocks JC Virus Entry – PR Newswire ATLANTA, Aug. 16, 2011 /PRNewswire/ — Inhibikase Therapeutics, Inc., an emerging leader in…
Stuart Schlossman
Understanding the Complexities of JCV and PML
Now Available Online at www.neurologyreviews.com Clinical Reviews of JCV and PML: Understanding the Complexities of JCV and PML This new…
Stuart Schlossman
Unilabs to Develop Companion Dx for Biogen Idec Drug
July 6, 2011 By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Unilabs will develop a companion diagnostic assay for…
Stuart Schlossman
Update Shows Higher Incidence of Natalizumab-Associated PML
Kate Johnson – Authors and Disclosures June 7, 2011 (Montreal, Quebec) — Numbers are higher than previously reported for the…
Stuart Schlossman
Natalizumab Has Minimal Effect on Vaccine Response
HONOLULU – Patients taking natalizumab showed similar or only slightly delayed humoral immune responses following vaccinations, compared with patients not…
Stuart Schlossman
The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis
The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis,…
Stuart Schlossman
